"the reality of the current situations" is this: There will be no approvals and no revenues in 2020. Period. And in the end, BP and FDA will bring the majority of CYDY shareholders to the brink of such a nervous breakdown that they will be more than happy to accept a BO at $3-4 billion and even send nice Christmas cards to Gilead board members for their generosity. And this will be the best of all scenarios, because what is more likely is that BP is not interested in buying this molecule at all. They want to eliminate it since leronlimab threatens to bankrupt them by making hundreds of their billions-making drugs obsolete.

Now some China-haters on this board raise a hue and cry about Chinese re-engineering leronlimab as soon as our cash-stripped company sells them a batch of Lero. But Chinese will eventually re-engineer Lero anyway, whether we like it or not. Or do you really think that this workshop of the world will be paying us 150K annually for each Chinese patient in the next 30 years? It's just that we won't get a penny for this while by selling our know how today we can get paid enough to get our cancer basket and any other trial in the world done. How much? I think somewhere in the region of $15 billion. For China it's less than a pocket change. For us and the millions of sufferers here and around the world it's a breakthrough. And something else. Just imagine the faces of those characters in the boardrooms of a Gilead or a GSK when the news come of the Chinese buying the license to produce and distribute Leronlimab for 4 billion customers in Asia. I'd give half of my CYDY shares to see this.

And there is another option.

We can let those 30-40 thousand ampules patriotically expire on the shelves. How long it'll take? 3-4 months at the most.